Literature DB >> 1678600

Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.

P A Humphrey1, L M Gangarosa, A J Wong, G E Archer, M Lund-Johansen, R Bjerkvig, O D Laerum, H S Friedman, D D Bigner.   

Abstract

Malignant human glioma D-298 MG amplifies a rearranged epidermal growth factor receptor (EGFR) gene (c-erbB proto-oncogene), resulting in an in-frame deletion of 83 amino acids in domain IV of the extracellular domain of the EGFR. EGF and transforming growth factor-a (TGF-a) bound to the mutant EGFR with high affinity and enhanced the intrinsic mutant EGFR kinase activity. The mutant EGFR was capable of transducing EGF-stimulated glioma cell proliferation and invasiveness in an in vitro three-dimensional spheroid model. The deletion-mutant EGFR in D-298 MG is capable of being activated by growth factor; this suggests that overexpression of this mutant EGFR protein rather than structural alteration may be the more significant biologic event.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678600     DOI: 10.1016/0006-291x(91)91051-d

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

Review 1.  Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors.

Authors:  D M Ashley; S K Batra; D D Bigner
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

Review 2.  Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.

Authors:  Gur Pines; Wolfgang J Köstler; Yosef Yarden
Journal:  FEBS Lett       Date:  2010-04-11       Impact factor: 4.124

Review 3.  Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.

Authors:  Frank B Furnari; Timothy F Cloughesy; Webster K Cavenee; Paul S Mischel
Journal:  Nat Rev Cancer       Date:  2015-04-09       Impact factor: 60.716

4.  A monoclonal antibody targeted against epidermal growth factor receptor variant III enhances cisplatin efficiency.

Authors:  Na Li; Yuanyuan Chu; Liangqing Yao; Xiaojun Ying; Hua Jiang; Ming Zhou; Congjian Xu
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-02       Impact factor: 4.553

5.  Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

Authors:  Klaus Koefoed; Lucilla Steinaa; Josefine Nielsen Søderberg; Ida Kjær; Helle Jane Jacobsen; Per-Johan Meijer; John Sørensen Haurum; Allan Jensen; Michael Kragh; Peter Sejer Andersen; Mikkel Wandahl Pedersen
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 6.  Mechanisms of tumor resistance to EGFR-targeted therapies.

Authors:  Elizabeth A Hopper-Borge; Rochelle E Nasto; Vladimir Ratushny; Louis M Weiner; Erica A Golemis; Igor Astsaturov
Journal:  Expert Opin Ther Targets       Date:  2009-03       Impact factor: 6.902

7.  Development of an EGFRvIII specific recombinant antibody.

Authors:  Puja Gupta; Shuang-Yin Han; Marina Holgado-Madruga; Siddhartha S Mitra; Gordon Li; Ryan T Nitta; Albert J Wong
Journal:  BMC Biotechnol       Date:  2010-10-07       Impact factor: 2.563

8.  Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells.

Authors:  Vineet Sangar; Cory C Funk; Ulrike Kusebauch; David S Campbell; Robert L Moritz; Nathan D Price
Journal:  Mol Cell Proteomics       Date:  2014-07-05       Impact factor: 5.911

Review 9.  Passive immunotherapeutic strategies for the treatment of malignant gliomas.

Authors:  Daniel T Nagasawa; Christina Fong; Andrew Yew; Marko Spasic; Heather M Garcia; Carol A Kruse; Isaac Yang
Journal:  Neurosurg Clin N Am       Date:  2012-07       Impact factor: 2.509

Review 10.  Genetics of primary brain tumors: a review.

Authors:  M Bondy; J Wiencke; M Wrensch; A P Kyritsis
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.